Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer
Open Access
- 1 February 2000
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 11 (2), 177-181
- https://doi.org/10.1023/a:1008360118617
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III TrialJournal of Clinical Oncology, 1999
- Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 StudyJournal of Clinical Oncology, 1999
- Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate CancerJournal of Clinical Oncology, 1999
- Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate CancerJournal of Clinical Oncology, 1999
- Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate CancerJNCI Journal of the National Cancer Institute, 1999
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist.Endocrine Journal, 1997
- Induction of Apoptosis by Diethylstilbestrol in Hormone-Insensitive Prostate Cancer CellsJNCI Journal of the National Cancer Institute, 1996
- How Much Can We Rely on the Level of Prostate-Specific Antigen as an End Point for Evaluation of Clinical Trials? A Word of Caution!JNCI Journal of the National Cancer Institute, 1996
- Diethylstilbestrol induces metaphase arrest and inhibits microtubule assemblyMutation Research Letters, 1985